Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know
Korean Journal of Radiology
;
: 42-53, 2017.
Article
in English
| WPRIM
| ID: wpr-208836
ABSTRACT
Over the past five years immune-checkpoint inhibitors have dramatically changed the therapeutic landscape of advanced solid and hematologic malignancies. The currently approved immune-checkpoint inhibitors include antibodies to cytotoxic T-lymphocyte antigen-4, programmed cell death (PD-1), and programmed cell death ligand (PD-L1 and PD-L2). Response to immune-checkpoint inhibitors is evaluated on imaging using the immune-related response criteria. Activation of immune system results in a unique toxicity profile termed immune-related adverse events. This article will review the molecular mechanism, clinical applications, imaging of immune-related response patterns and adverse events associated with immune-checkpoint inhibitors.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
T-Lymphocytes, Cytotoxic
/
Cell Death
/
Hematologic Neoplasms
/
Precision Medicine
/
Immune System
/
Antibodies
Type of study:
Prognostic study
Language:
English
Journal:
Korean Journal of Radiology
Year:
2017
Type:
Article
Similar
MEDLINE
...
LILACS
LIS